The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility.

Natasha B Hunter Mark R KilgoreNancy E Davidson

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Tumor data from the ABCSG 5 trial of chemotherapy versus endocrine therapy for premenopausal ER+ breast cancer supports molecular subtyping by Ki-67 IHC as a prognostic marker. But while this tissue was handled uniformly, Ki-67 testing overall is unstandardized, complicating clinical utility. Increasing potential biomarkers herald more challenges in biomarker validation.See related article by Bago-Horvath et al., p. 5682.

Keyphrases

neoadjuvant chemotherapy
breast cancer risk
clinical trial
study protocol
locally advanced
electronic health record
postmenopausal women
randomized controlled trial
lymph node
estrogen receptor
young adults
drug induced
chemotherapy induced
clinical evaluation